S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

UK vaccination drive expands as virus toll nears 100,000


People sit and relax after receiving their Pfizer-BioNTech vaccination at Salisbury Cathedral in Salisbury, England, Wednesday, Jan. 20, 2021. Salisbury Cathedral opened its doors for the second time as a venue for the Sarum South Primary Care Network COVID-19 Local Vaccination Service. (AP Photo/Frank Augstein)

LONDON (AP) — Britain is expanding a coronavirus vaccination program that has seen more than 6 million people get the first of two doses — even as the country’s death toll in the pandemic approaches 100,000.

Health Secretary Matt Hancock said Sunday that three-quarters of the U.K.’s over-80s have received a vaccine shot. He said three-quarters of nursing home residents have also had their first jab.

Health authorities said 6.35 million doses of vaccine have been administered since injections began last month, including almost 500,000 doses on Saturday, the highest one-day total so far. Health officials aim to give 15 million people, including everyone over 70, a first vaccine shot by Feb. 15, and cover the entire adult population by September.

Britain is inoculating people with two vaccines — one made by U.S. pharma firm Pfizer and German company BioNTech, the other by U.K.-Swedish drugmaker AstraZeneca and Oxford University. It has also authorized a third, developed by Moderna.

It is giving the shots at doctors’ offices, hospitals, pharmacies and vaccination centers set up in conference halls, sports stadiums and other large venues like Salisbury Cathedral. Thirty more locations are opening this week, including a former IKEA store and a museum of industrial history that was used as a set for the TV show “Peaky Blinders.”

Britain’s vaccination campaign is a rare success in a country with Europe’s worst confirmed coronavirus outbreak. The U.K. has recorded 97,939 deaths among people who tested positive, including 610 new deaths reported Sunday.

The U.K. is set within days to become the fifth country in the world to record 100,000 COVID-19 deaths, after the United States, Brazil, India and Mexico — all of which have much larger populations than Britain's 67 million people.

Some health experts have questioned the Conservative government’s decision to give the two vaccine doses up to 12 weeks apart, rather than the recommended three weeks, in order to offer as many people as possible their first dose quickly.


AstraZeneca has said it believes a first dose of its vaccine offers protection after 12 weeks but Pfizer says it has not tested the efficacy of its jab after such a long gap.

The British Medical Association says the government should “urgently review” the policy.

But Anthony Harnden, deputy head of the government-advising Joint Committee on Immunization and Vaccination, defended the policy, saying the U.K. is in a “dire situation.”

“Every dose of vaccine we give as a second dose, we’ll be denying somebody their first dose at the moment and denying them very good protection,” Harnden told Sky News. He said the policy of prioritizing first doses would “save thousands and thousands of lives.”

Britain’s latest surge is being fueled in part by a new virus variant first identified in southeast England, which scientists believe is more transmissible than the original strain. They also say it may be more lethal, though that evidence is weaker.

The British government has said it may tighten quarantine requirements for people arriving from abroad in an attempt to keep out other new variants discovered in South Africa and Brazil. Already travelers to Britain must self-isolate for 10 days, but enforcement is patchy. Authorities are considering requiring arrivals to stay in quarantine hotels like those set up in Australia and some other countries.

The U.K. is several weeks into a lockdown to try to slow the spread of the virus. Pubs, restaurants, gyms, entertainment venues and many shops are closed, and people are required to stay largely at home.

The lockdown rules will be reviewed on Feb. 15, but the government says it is too soon to think about easing the restrictions.

“There is early evidence that the lockdown is starting to bring cases down, but we are a long, long, long way from being low enough,” Hancock said.

___

Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic,https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9926 of 5 stars
$25.39-0.1%6.62%70.51Hold$36.88
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

7 Stocks to Help You Build Off January’s Gains

7 Stocks to Help You Build Off January’s Gains

It's frequently said that as January goes, so goes the market. If that's the case, it's time for investors to put money to work in the stock market.

Search Headlines: